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Proton Pump Inhibitors (PPIs) taken for ≥1 year have been linked to increased fragility 
fracture (FF) risk, prompting the US FDA to issue a related  warning.  
The oldest old (≥85) and patients with co-morbidities may be at greater risk;(1) however little 
or no evidence has been available in these groups of vulnerable people.  
In this retrospective matched-cohort study with difference-in-difference methods, we 
investigated the 4-year FF risk in older patients (≥60) and patients with co-morbidities.  
Methods  
We used the Clinical Practice Research Datalink, a database of primary care electronic 
medical records linked to hospital records. The sample included 86,469 patients receiving 
PPIs for ≥1 year and 86,469 age- and gender-matched controls, registered with a primary care 
practice in England between April 1997 and March 2014.  
PPIs (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole) were identified in 
the electronic prescribing data and analyzed as a class, regardless of dosage. The date of the 
first PPI prescription for the treated member of each matched pair was deemed the pair’s 
index date.  
FFs, were defined by hospitalization for new spine, hip, wrist, humerus, pelvis, ankle and rib 
fracture, coded using ICD-10. Patients with FFs within 3 months before their first PPI 
prescription were excluded, to avoid bias.(2)  
Cox’s regressions were used to compare FF risk during the 4 years before (pre-treatment 
period) and after (treatment period) index date. According to the Prior Event Rate Ratio 
(PERR) approach,(3) a difference-in-difference method, hazard ratios in the pre-treatment 
period were used to correct the treatment period hazard ratios. PERR was used to address 
both measured and unmeasured confounding, the latter being a major caveat in the 
interpretation of current evidence.(4)  
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Results were stratified by age (60-74, 75-84, and ≥85) and co-morbidity (Charlson 
Comorbidity Index, 0 and ≥1). Numbers needed to harm (NNHs) were also calculated.(5) 
Subgroups were compared using confidence intervals since interactions cannot be tested 
using PERR. 
Results  
The mean age was 71.9 (±7.9) years. FF rates in people aged ≥60 and those 60-74, 75-84, and 
≥85 were 11.7, 7.3, 18.5, and 33 per 1000 person-years, respectively.     
Differences at index date between treatment groups (table) were reflected by higher hazard 
ratios in patients exposed to PPIs in both pre-treatment and treatment periods (figure). 
Measured and unmeasured confounding has been addressed using PERR.  
In the adjusted analysis (net estimates, figure) across the studied age-range, patients receiving 
PPIs were at greater risk of FF than controls (PERR adjusted Hazard Ratio 1.27: 95%CI 1.16 
to 1.34) after accounting for prior differences in FF rates. The Hazard Ratio for PPI use in 
those aged ≥85 overlapped with that in younger groups and were similar in patients with and 
without co-morbidity. Sensitivity analyses excluding people with corticosteroids co-
prescription and their matched pairs showed similar results (HR: 1.23, 95%CI: 1.05-1.44).   
Since the hazard estimates were similar in age and co-morbidity subgroups, subgroup-
specific NNHs were calculated by applying the full-sample risk estimate to subgroup-specific 
FF rates. (5) The NNH for FF in all patients aged ≥60 was 121 (95%CI 81 to 222) over 4 
years. NNH in patients ≥85 (45, 30 to 81) was lower than that in ages 60-74 (207, 141 to 368) 
but similar in patients with and without co-morbidity (data not shown).  
Conclusion  
This observational study, using a validated method to address unmeasured confounding, 
confirms an approximately 30% increased FF risk in older patients receiving PPIs for ≥1 
year. Although there were similar excess  risks in patients aged ≥85, given the higher 
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absolute risk of FF in this group, only 45 patients  need to be treated to harm one, suggesting 
that PPIs should be used with caution especially for symptomatic relief in this group. In the 
UK the vast majority of people aged ≥60 receive free drug prescriptions and the ≥1 year over-
the-counter PPI use is therefore limited and unlikely to bias our results. 
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Table: Percent of selected characteristics at index date 
Characteristic*  
Controls Treated 
N=86,469 N=86,469 
Age group 
 
    60-74 66.1 66.1 
    75-84 27.7 27.7 
    85+ 6.3 6.3 
Gender (women) 56.4 56.4 
Ethnicity 
  
    White 60.2 79.9 
    Non-white 1.4 2.5 
    Not recorded /Undisclosed 38.5 17.5 
Poorer socio-economic status  
50.3 52.2 (3rd-5th quintile of Index of  
Multiple Deprivation) 
Body Mass Index 
 
    Underweight (<18.5 kg/m
2
) 1 1 
    Normal (18.5-24.9 kg/m
2
) 17.3 18.4 
    Overweight (25-29.9 kg/m
2
) 20.4 25.8 
    Obese (≥30 kg/m2) 12.7 18.1 
    Unrecorded 48.5 36.8 
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Characteristic* 
 
Controls Treated 
N=86,469 N=86,469 
Smoking status 
  
    Never smokers 44.6 41 
    Ex-smokers 17.6 21.9 
    Current smokers 28 32.6 
    Not recorded 9.8 4.4 
Alcohol drinking 
  
    Never/currently not 9 10.6 
    Current, known amount 42.2 47.2 
    Heavy 9.4 12 
    Current, unknown amount 0.9 1 
    Former 2.2 3 
    Undetermined 36.4 26.2 
Charlson Comorbidity Index (≥1) 39.8 57.6 
Falls (within a year before baseline) 11.6 16.6 
Anaemia 2.7 7.7 
Ischemic stroke 5.5 9.3 
Coronary heart disease 10.5 20.1 
Osteoporosis 3.6 6 
Osteoarthritis 19.9 32.6 
Gastroesophageal reflux disease 0.2 4.6 
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Characteristic* 
Controls Treated 
N=86,469 N=86,469 
Vitamin D supplement 3.9 9 
Corticosteroids 25.2 44.3 
Oestrogen 2.2 4.4 
Testosterone 0.1 0.1 
Anti-thyroid drugs 0.2 0.3 
Levothyroxine 6 8.6 
*All differences (except for gender and age groups) between the PPI treated and controls 
significant at p<.001 (χ2). 
 
Legend to the Figure  
Hazard ratios for pre-treatment and treatment periods and PERR-adjusted hazard ratios for 
the full sample and by comorbidity and age groups (log-scale);  
HR= hazard ratio; 95%CI= 95% confidence interval; PERR: Prior Event Rate Ratio. CCI= 
Charlson Comorbidity Index; HR PERR = HR Treatment period / HR Pre-treatment period; confidence 
intervals for PERR analyses were calculated using bootstrapping techniques.   
 

